ILC Therapeutics completes GBP3.5m funding round
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, has completed a GBP3.5 million pre-IPO funding round. Investors include Los Angeles-based lawyer and investor, Robert Kopple; St Andrews-based Eos Angel Investment Syndicate; Scottish Enterprise; ILCT management. Chairman Peter

